Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Stifel slashes Hikma target price but stays positive

Wed 11 Mar 2026 12:40

(Sharecast News) - Stifel has slashed its target price for Hikma Pharmaceuticals by nearly a third but said it still sees significant upside, saying the recent sell-off represents a "good entry point" for new investors. The broker has cut its target price for the shares from 2,400p to 1,700p, though that still implies 40% potential upside from current levels after a 25% slump in the stock since FY25 results were released on 26 February.

Stifel said that the market has "lost confidence" which will take time to restore, with the jewel of the group - margin levels in the injectables division - disappointing as of late.

"Having thought the plaster had been ripped off in November 2025 when downgrading the Injectables operating margin from mid-30s to a new 'floor' of 30%, guidance for FY26 at 27-28% understandably spooked the market," Stifel said.

"Quite a swing, that has left the market searching for a floor and concerned that margin could erode further, making it harder to deliver profit growth which is needed to make the stock work."

Nevertheless, with the stock back down to 2022 levels, when the former Generics business was struggling - before management stabilised the business and rebased expectations - investors could prosper from buying the dip, Stifel said.

"We [...] accept that investors may want to see some positive proof points, but on balance, we believe the current price and near-three-year low valuation will prove to have been a good entry point."

Hikma shares were trading up 1.8% at 1,218p by 1455 GMT.

Share this article

Related Sharecast Articles

Thu 16 Jul 2026 14:42
RBC Capital Markets keeps Ashtead at 'outperform'
(Sharecast News) - RBC Capital Markets said first‑half trading at Ashtead Technology was solid, but slightly softer margins linked to ongoing Middle East and Asia disruptions prompted the broker to trim its estimates.
Thu 16 Jul 2026 14:30
St James's Place tumbles as two more appointed representatives leave
(Sharecast News) - St James's Place tumbled on Thursday following a report that two more of its large appointed representatives have left the network.
Thu 16 Jul 2026 14:17
Oxford Biomedica inks service deal with Plowshare Therapies
(Sharecast News) - Oxford Biomedica announced on Thursday that it has signed an agreement to provide process development and AAV GMP manufacturing services to Plowshare Therapies, supporting the biotechnology company's gene therapy programme for rare genetic diseases.
Thu 16 Jul 2026 12:21
Berenberg lowers target price on Rio Tinto following Q2 update
(Sharecast News) - Analysts at Berenberg cut their price target on Rio Tinto from 8,200p to 8,100p on Thursday, saying higher‑than‑expected diesel costs in the Pilbara were likely to keep unit‑cost pressure elevated, while parts of the miner's Q2 production update pointed to downside risks in iron ore.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Policies and important information
 

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme

 

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026